Patrick J. Stiff, Manza-A. Agovi, Karen H

Slides:

Advertisements

Similar presentations

Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Timothy S.

Advertisements

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report.

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report Ivana N.

Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma Ravi Vij, Shaji Kumar, Mei-Jie Zhang,

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond.

Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis Danielle H. Oh, Haocheng.

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents Thomas G. Gross, Gregory A. Hale,

Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age Years with Acute Myelogenous Leukemia in First.

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns

Biology of Blood and Marrow Transplantation

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma Navneet S. Majhail, Daniel J. Weisdorf,

Sabina Kersting, Leo F. Verdonck

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR Gregory.

Outcome of Transplantation for Myelofibrosis

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Childhood Obesity and Outcomes after Bone Marrow Transplantation for Patients with Severe Aplastic Anemia Collin C. Barker, Manza-A. Agovi, Brent Logan,

Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma Marcel P. Devetten,

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure César O. Freytes, Mei-Jie Zhang,

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Adjusting Cyclophosphamide Dose in Obese Patients with Lymphoma Is Safe and Yields Favorable Outcomes after Autologous Hematopoietic Cell Transplantation

Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International.

Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation Shaji Kumar, Waleska S. Pérez, Mei-Jie.

Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Anuj Mahindra, Brian Bolwell, Ronald.

Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.

Jeffrey Schriber, Manza-A. Agovi, Vincent Ho, Karen K

Comparison of Outcomes after Transplantation of G-CSF–Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

What is quality in a transplant program?

Richard Mitchell, John E. Wagner, Claudio Brunstein, Qing Cao, David H

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Risk Factors Affecting Outcome of Second HLA-Matched Sibling Donor Transplantations for Graft Failure in Severe Acquired Aplastic Anemia John T. Horan,

Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma Tanya M. Wildes, Kristan M. Augustin, Diane.

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow.

Mammen Chandy Biology of Blood and Marrow Transplantation

Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer Kim A. Margolin, James H. Doroshow, Paul Frankel,

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence Fausto R. Loberiza, Stephanie.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Presentation transcript:

High-Dose Chemotherapy with Blood or Bone Marrow Transplants for Rhabdomyosarcoma Patrick J. Stiff, Manza-A. Agovi, Karen H. Antman, Didier Blaise, Bruce M. Camitta, Mitchell S. Cairo, Richard W. Childs, John R. Edwards, Robert Peter Gale, Gregory A. Hale, Hillard M. Lazarus, Mukta Arora Biology of Blood and Marrow Transplantation Volume 16, Issue 4, Pages 525-532 (April 2010) DOI: 10.1016/j.bbmt.2009.11.020 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Probability of PFS and OS after autologous transplant for rhabdomyosarcoma patients. Biology of Blood and Marrow Transplantation 2010 16, 525-532DOI: (10.1016/j.bbmt.2009.11.020) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Probability of PFS and OS after autologous transplant for poor-risk RMS patients who relapsed prior to transplantation. Biology of Blood and Marrow Transplantation 2010 16, 525-532DOI: (10.1016/j.bbmt.2009.11.020) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions